Intelence Warning
Intelence (etravirine, a non-nuke) may, in rare cases, cause a serious rash. This can be linked to a hypersensitivity reaction including flulike symptoms and sometimes organ failure. If you’ve recently started Intelence and you develop a rash, contact your doctor about possibly discontinuing the drug. Updated prescribing information for Intelence says the reaction has generally appeared within six weeks of beginning the drug.
Isentress is now available for first timers
People taking HIV meds for the first time can now include Isentress (raltegravir) in their combo, the FDA says. In 2007, Isentress was approved only for people who’d been on most other available HIV meds. The dose of this integrase inhibitor is the same for both groups: a 400 mg tablet twice daily in a multidrug regimen.
Comments
Comments